Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis

Trial Profile

Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 New source identified and integrated (Roche; WP18046)
    • 02 Dec 2008 Actual end date changed from Nov 2006 to May 2006 as reported by Clinicaltrials.gov.
    • 19 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top